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Finasteride, a type 2-selective 5a-reductase inhibitor,
was approved in 1997 as the ¢rst oral pharmacologic
therapy for the treatment of men with androgenetic
alopecia (AGA; male pattern hair loss). Originally de-
veloped for the treatment of men with benign prostatic
hyperplasia (BPH) at a dose of 5 mg/day, ¢nasteride has
a well-established, excellent safety pro¢le. Subsequent
studies demonstrated that ¢nasteride was an e¡ective
treatment for men with AGA at an optimal dose of
1 mg/day. This report summarizes the published
peer-reviewed literature on the use of ¢nasteride in the
treatment of men with AGA, including the data on
long-term (5 years) use of ¢nasteride in a placebo-con-
trolled clinical trial environment. Key words: type 2 5a-
reductase/¢nasteride/dihydrotestosterone/androgenetic alopecia/
male pattern hair loss. JID Symposium Proceedings 8:20 ^23,
2003
INITIAL CLINICAL STUDIES WITH FINASTERIDE IN
MEN WITH ANDROGENETIC ALOPECIA
D
rake et al (1999) reported on the biochemical e⁄cacy
of ¢nasteride in men with androgenetic alopecia
(AGA), demonstrating that median scalp dihydro-
testosterone DHT levels were decreased by 64%
and 69% after 42 days of treatment at doses of
1 mg and 5 mg, respectively, compared to a 13% decrease with
placebo. Median serum DHT levels decreased 71% and 72%, re-
spectively, compared to a 1% increase with placebo. This study
also demonstrated that at doses as low as 0.05 mg daily, ¢nasteride
signi¢cantly decreased scalp DHT, although only dosesX0.2 mg
were near-maximally e¡ective in decreasing both scalp and
serum DHT.
Roberts et al (1999) reported on clinical dose-ranging studies
with ¢nasteride at doses of 5, 1, 0.2 and 0.01 mg/day in men with
AGA.These studies demonstrated that ¢nasteride treatment led to
both an increase in hair count and cosmetic improvement in hair
growth, establishing for the ¢rst time the proof of concept for
the e⁄cacy of ¢nasteride in the treatment of men with AGA.
The e⁄cacy of ¢nasteride 1 mg was similar to the e⁄cacy ob-
served with the 5-mg dose but was signi¢cantly greater than the
e⁄cacy observed with lower doses (0.2 mg and 0.01mg) of ¢nas-
teride. The 1-mg dose was generally well tolerated by patients,
and its safety pro¢le was similar to that seen with lower doses of
¢nasteride or placebo. The 1-mg dose was thus chosen as optimal
for further study in subsequent Phase III studies in men with
AGA.
PHASE III STUDIES WITH FINASTERIDE IN MEN WITH
ANDROGENETIC ALOPECIA
Three double-blind, randomized, placebo-controlled Phase III
studies of ¢nasteride were conducted in 1879 men ages 18^41
years with mild to moderate AGA (Kaufman et al, 1998; Leyden
et al, 1999). Two of the studies enrolled men with predominantly
vertex hair loss (n¼1553; Kaufman et al, 1998) and one study en-
rolled men with predominantly frontal (anterior mid-scalp) hair
loss (n¼ 326; Leyden et al, 1999). Finasteride 1 mg or matching
placebo tablets were taken once daily for 24 months in the vertex
studies and for 12 months in the frontal study. All three studies
demonstrated that ¢nasteride treatment led to a signi¢cant im-
provement in hair growth and slowing of further hair loss pro-
gression, while placebo-treated men showed signi¢cant hair loss.
In the Phase III vertex hair loss studies, treatment with ¢naster-
ide 1 mg/day produced clinical bene¢t relative to baseline or pla-
cebo for all four prede¢ned endpoints: hair counts obtained in a
de¢ned, representative area of scalp hair loss; patient self-adminis-
tered assessment of hair growth; investigator clinical assessment
of hair growth; and blinded assessment of standardized clinical
photographs by an expert panel of dermatologists (global photo-
graphic assessment).
The assessment of standardized clinical photographs by the ex-
pert panel demonstrated that improvement in hair growth oc-
curred in 48% of ¢nasteride-treated men at one year, compared
with 7% of men receiving placebo. The bene¢t of ¢nasteride in-
creased further at two years: 66% of men were rated as having
improved hair growth based on assessment of standardized clini-
cal photographs, compared with 7% of men receiving placebo.
The ¢nasteride-related improvements in hair growth, based on
assessment of standardized clinical photographs, were associated
with increased hair density, based on hair counts obtained in a
standardized, 1-inch diameter, circular target area centered at the
anterior leading edge of the vertex bald spot. Treatment with ¢-
nasteride led to an 11% mean increase in hair count compared to
baseline at 1 year, and this improvement was maintained at
2 years. In contrast, men treated with placebo were documented
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by hair count to have sustained progressive hair loss over 2 years.
The net improvement in hair count (¢nasteride vs. placebo) was
thus 14% at 1year and 16% at 2 years. Only 17% of men receiving
¢nasteride lost hair based on hair count during the 2-year studies,
compared with 72% of men receiving placebo. These data de-
monstrated that ¢nasteride slowed the progression of hair loss.
Despite mean hair counts being stable between years 1 and 2 for
¢nasteride-treated patients, assessment of standardized clinical
photographs demonstrated further improvement in these men
between years 1 and 2. This ¢nding indicated that treatment with
¢nasteride produced further improvements in hair quality be-
tween the ¢rst and second year. The clinical relevance of these
improvements was supported by the improvements reported by
patients based on a self-administered hair growth questionnaire.
Analysis of this validated instrument indicated that the majority
of men reported slowing of scalp hair loss, increased scalp hair
growth, improved appearance of scalp hair, and increased satisfac-
tion with the appearance of scalp hair by 2 years, and these
changes were superior to those reported by men treated with pla-
cebo. Analysis of the investigators’ clinical assessment of patients’
scalp hair also con¢rmed that ¢nasteride treatment improved
scalp hair growth compared to treatment with placebo.
Some subjects in the vertex hair loss studies were randomly
crossed over after 1 year from treatment with ¢nasteride to treat-
ment with placebo and showed loss of the bene¢t achieved in the
¢rst year by hair count and standardized clinical photography.
Other subjects were randomly crossed over from treatment with
placebo to treatment with ¢nasteride after 1year and showed sig-
ni¢cant gains. For subjects treated continuously with ¢nasteride
1 mg, hair count increases above baseline were maintained
throughout the 2 years of the studies.
The Phase III vertex hair loss studies demonstrated that ¢nas-
teride 1 mg/day has an excellent safety pro¢le. As in all clinical
studies with ¢nasteride, a marked and persistent suppression of
serum DHT levels was observed in ¢nasteride-treated subjects,
but this was not associated with signi¢cant changes in serum go-
nadotropins (luteinizing hormone (LH) and follicle-stimulating
hormone (FSH)). These data are consistent with previous data
on the lack of e¡ect of ¢nasteride on the hypothalamic pitui-
tary-gonadal axis in young men. As expected, based on the pre-
viously reported experience with ¢nasteride, a few men in the
vertex hair loss studies experienced reversible impairment of sex-
ual function. Drug-related adverse events reported by X1% of
men receiving ¢nasteride 1 mg in the ¢rst year were decreased
libido (reported by 1.8% of men on ¢nasteride vs. 1.3% on place-
bo), erectile dysfunction (reported by 1.3% of men on ¢nasteride
vs. 0.7% on placebo) and ejaculation disorder (1.2% of men on
¢nasteride vs. 0.7% on placebo). Approximately 1% (1.2%) of
men receiving ¢nasteride discontinued treatment due to these ad-
verse events (compared with 0.9% of men in the placebo group)
with resolution occurring after discontinuation of drug. No other
signi¢cant adverse e¡ects of ¢nasteride were observed in the pa-
tient population evaluated in these clinical studies. This excellent
safety pro¢le is consistent with prior experience with ¢nasteride
at ¢ve times the dose used in these studies, and has been well-
documented in large clinical trials and postmarketing surveil-
lance in men with benign prostatic hyperplasia (BPH) for nearly
10 years. A modest reduction in serum prostate-speci¢c antigen
(PSA) was also observed in ¢nasteride-treated subjects. In light
of the well-known inhibitory e¡ect of ¢nasteride on the growth
of the prostate gland in men with BPH, this decrease in PSAwas
not unexpected. For men in whom serum PSA is used as part of a
screening evaluation for prostate cancer, guidelines have been
published for interpretation of PSA levels in men receiving ¢nas-
teride treatment.
The Phase III frontal hair loss study was conducted in parallel
with the Phase III vertex hair loss studies in order to evaluate the
e⁄cacy of ¢nasteride 1 mg primarily in the anterior mid-scalp
area, as opposed to the vertex. The frontal hair loss study used
similar endpoints to those used in the vertex studies and demon-
strated signi¢cant improvements in all prede¢ned e⁄cacy mea-
sures with ¢nasteride compared with placebo. Treatment with
¢nasteride signi¢cantly improved anterior mid-scalp hair counts
and led to cosmetic improvement noted by patients, investigators,
and the expert panel reviewing standardized clinical photographs.
Based on the ¢ndings from the Phase III vertex and frontal
hair loss studies, it can be concluded that ¢nasteride is generally
well tolerated and leads to improvements in hair growth in men
with AGA, and slows the further progression of hair loss that oc-
curs without treatment. Continued daily use of 1-mg oral ¢nas-
teride is needed for sustained bene¢t. Based on hair counts, no
further hair loss was observed in 83% of ¢nasteride-treated men
with vertex hair loss after 2 years and in 70% of ¢nasteride-treat-
ment men with frontal hair loss after 1 year. Based on standar-
dized clinical photography, the chances of mild to moderate
visible regrowth are 61% on the vertex (with an additional 5%
achieving great visible regrowth) after 2 years and 37% on the
frontal area after 1year.
5-YEAR PLACEBO-CONTROLLED EXTENSIONS TO
PHASE III VERTEX STUDIES
The previously described 2-year Phase III vertex hair loss studies
were extended for up to 5 years of placebo-controlled observa-
tions (Finasteride Male Pattern Hair Loss Study Group, 2002).
The results of these 5-year studies demonstrated that long-term
treatment with ¢nasteride led to durable improvements in scalp
hair compared to treatment with placebo in men with AGA.
Hair counts, which increased with ¢nasteride treatment during
the ¢rst year of the study, remained above baseline over 5 years.
In contrast, men treated with placebo progressively lost hair over
5 years, con¢rming the e¡ect of continued miniaturization of
scalp hair that is the hallmark of this disorder.Thus, the treatment
e¡ect of ¢nasteride on hair count relative to placebo increased
progressively over time, leading to a net improvement for ¢nas-
teride-treated men of 277 hairs in the target area compared to
placebo at 5 years. Most (65%) ¢nasteride-treated men had in-
creases in hair count at 5 years, compared to none of the placebo-
treated men, but even for those ¢nasteride-treated men with a
lower hair count at ¢ve years compared to baseline, the average
magnitude of loss was less than that observed in the placebo
group. These data support that the progression of hair loss ob-
served in placebo-treated men was signi¢cantly reduced by treat-
ment with ¢nasteride.
Similarly, expert panel review of standardized clinical photo-
graphs con¢rmed the bene¢t of ¢nasteride treatment: 90% of ¢-
nasteride-treated men either maintained (no further visible hair
loss from baseline), or sustained visible improvement in, scalp cov-
erage over 5 years, while 75% of placebo-treated men sustained
visible deterioration in scalp coverage (Fig 1). The investigators’ as-
sessments also demonstrated a sustained bene¢t of ¢nasteride treat-
ment over 5 years. Although there was no further improvement
reported for ¢nasteride-treated subjects between 2 and 5 years by
this assessment, there was signi¢cant deterioration reported for
placebo-treated subjects during the same time period. Thus, the
treatment e¡ect of ¢nasteride, compared to placebo, as assessed by
the investigators increased between 2 and 5 years, indicating
further separation between the treatment groups over time.
Analysis of the patient self-assessment data demonstrated the
relevance of the bene¢t of ¢nasteride from the patient’s perspec-
tive. Men treated with ¢nasteride had a more positive self-assess-
ment of their hair growth and satisfaction with their appearance
than men treated with placebo, with the majority of ¢nasteride-
treated men reporting satisfaction with the overall appearance of
their scalp hair at 5 years (Fig 2). Consistent with the ¢ndings of
the Phase III frontal hair loss study, patients’ satisfaction with the
appearance of their frontal hairline was improved by treatment
with ¢nasteride in the vertex hair loss studies at 5 years.
No new side-e¡ects were reported from these long-term clin-
ical trials, and the incidence of side-e¡ects reported in the ¢rst
year decreased with continued use.
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In summary, the results of the two 5-year Phase III vertex hair
loss studies con¢rm and extend the ¢ndings from the published
2-year results of these studies. Long-term treatment with ¢nas-
teride was generally well tolerated and led to signi¢cant and dur-
able improvements in hair growth while slowing the further
progression of hair loss that occurred without treatment in men
with AGA.
STUDIES EXAMINING MECHANISM(S) UNDERLYING
FINASTERIDE’S BENEFICIAL EFFECTS ON HAIR
GROWTH IN MEN WITH ANDROGENETIC ALOPECIA
A number of clinical studies have been conducted to examine
the mechanism(s) by which ¢nasteride may produce its bene¢cial
e¡ects on hair growth in men with AGA. Whiting et al (1999)
conducted a histologic study of scalp biopsies taken from men at
baseline and after 12 months of treatment with either ¢nasteride
1 mg or placebo. This study demonstrated that treatment with ¢-
nasteride led to a signi¢cant increase in terminal anagen hairs
after 12 months compared to placebo. Histologically, a trend to-
wards a decrease in vellus-like miniaturized hairs and an increase
in the terminal to vellus ratio was observed in the ¢nasteride
group compared to the placebo group, suggesting reversal of the
miniaturization process with ¢nasteride.
A second study by Van Neste et al (2000) using the phototri-
chogram method provided direct evidence that treatment with
¢nasteride 1mg promotes the conversion of hairs into the anagen
phase. This study enrolled 212 men ages 18^40 years with AGA,
randomized to either ¢nasteride 1 mg or placebo daily for
48 weeks. Macrophotographs were taken to measure both total
and anagen hair counts in a 1-cm2 target area of the vertex scalp.
At 48 weeks, treatment with ¢nasteride signi¢cantly increased
both total and anagen hair counts and improved the anagen/telo-
gen ratio, resulting in a net improvement in the anagen/telogen
ratio of 47% compared to placebo.
EFFECTS OF FINASTERIDE IN WOMEN WITH
ANDROGENETIC ALOPECIA
In contrast to all of the studies described above, which were con-
ducted in men with AGA, a study of ¢nasteride in postmenopau-
sal women with AGA showed no bene¢t (Price et al, 2000). In this
1-year, double-blind, randomized, placebo-controlled trial, 137
postmenopausal women (41^60 years of age) with AGA received
¢nasteride 1 mg/day or placebo. E⁄cacy was evaluated by scalp
hair counts, patient and investigator assessments, ratings of stan-
dardized clinical photographs by an expert panel, and histologic
analysis of scalp biopsies. Although ¢nasteride was generally well
tolerated, after 1year of treatment there was no signi¢cant di¡er-
ence in the change in hair count between the ¢nasteride and pla-
cebo groups, and decreases in hair count in the frontal/parietal
scalp were observed in both treatment groups. Similarly, patient,
investigator, and standardized clinical photographic assessments
did not demonstrate improvement in slowing hair loss, increasing
hair growth, or improving the appearance of scalp hair in ¢nas-
teride-treated subjects compared with the placebo group. These
¢ndings were con¢rmed by histologic analysis of scalp biopsies
from women participating in the trial (n¼ 94; Whiting et al,
1999; Price et al, 2000), which also showed no improvement.
CONCLUSION
5a-reductase inhibitors were developed approximately 20 years
ago. Their subsequent use as tools to understand both androgen
biology and disease pathophysiology has led to an understanding
of the key role DHT plays in the pathophysiology of AGA in
men. Finasteride was the ¢rst, highly speci¢c inhibitor of the
human type 2 5a-reductase enzyme developed for clinical use.
Accumulated data from multicenter clinical trials have established
¢nasteride’s importance as a treatment for men with androgen-
dependent disorders, including AGA. Finasteride’s mechanism of
action, which leads to reduced levels of DHT when the drug is
administered orally, represents a rational approach to the treat-
ment of men with AGA. Because it is a systemic medication,
¢nasteride is delivered to the entire scalp, including the a¡ected
areas.The clinical studies demonstrated responsiveness to ¢naster-
ide treatment across a broad range of men with AGA, those with
mild to moderate degrees of hair loss in the vertex and anterior
mid-scalp areas. No signi¢cant clinical or laboratory adverse
e¡ects have been observed with ¢nasteride that preclude its
long-term use by men. Moreover, ¢nasteride is not a new drug,
and worldwide experience with a higher dose of ¢nasteride over
many years in the treatment of men with BPH con¢rms the
Figure1. Finasteride treatment led to no further visible hair loss
from baseline in the majority of men over 5 years of observation,
based on expert panel review of standardized clinical photographs
for the cohort of patients in the combined Phase III vertex hair loss
studies who entered the last (¢fth) placebo-controlled extension
studies. Conversely, most (75%) men treated with placebo sustained
further visible hair loss at 5 years.
Figure 2. Finasteride treatment led to a more positive self-assess-
ment of scalp hair appearance compared with placebo over 5 years
of observation. One-year and 5-year data are shown for the percent of
men who self-reported their degree of satisfaction with the overall appear-
ance of their scalp hair compared with baseline for the cohort of patients in
the combined Phase III vertex hair loss studies who entered the last (¢fth)
placebo-controlled extension studies.
22 SHAPIROAND KAUFMAN JID SYMPOSIUM PROCEEDINGS
long-term safety of the compound. The e¡ectiveness of ¢naster-
ide in the treatment of men with androgen-dependent disorders,
including AGA, has prompted the development of other inhibi-
tors of 5a-reductase, as well as increasing research in modulators
of androgen action, for potential use in treating men with these
disorders.
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